Garg Vipin K 4

What Happened
Vipin K. Garg, a director of Altimmune, had 26,775 restricted stock units (RSUs) convert into common shares on 2026-01-30 (exercise/conversion at $0.00). To satisfy tax withholding, 11,632 of those shares were surrendered to the company (reported as disposed) for a value of $65,139 ($5.60 per share). On 2026-01-31 he also acquired 6,926 shares under the company’s Employee Stock Purchase Plan (ESPP) at $3.07 per share for $21,263. Net new shares received from these events = 22,069 (15,143 net from RSU vesting + 6,926 ESPP).

Key Details

• Transaction dates: RSU conversion and tax withholding on 2026-01-30; ESPP purchase on 2026-01-31. Filing date: 2026-02-02 (timely).
• Prices/values: RSU conversion recorded at $0.00 (no exercise cash paid); 11,632 shares withheld at $5.60 = $65,139; ESPP purchase 6,926 shares @ $3.07 = $21,263.
• Shares owned after transaction: total holdings not disclosed in the provided excerpt; net shares received from these events = 22,069.
• Footnotes of note: F1–F2 explain RSUs are contingent rights to shares and that shares were surrendered solely to cover taxes; F3–F4 state the ESPP purchase covers the Aug 1, 2025–Jan 31, 2026 period and was priced at 85% of the Aug 1, 2025 closing price; F5 describes the RSU vesting schedule (4 annual installments beginning Jan 30, 2023).
• Transaction codes: M = exercise/conversion of derivative (RSU vesting), F = tax withholding (shares surrendered), A = award/ESPP acquisition.

Context

• This appears to be routine RSU vesting with shares withheld to cover tax obligations (a cashless withholding), plus a regular ESPP purchase — not an open-market sale that would necessarily signal a change in insider sentiment.
• The RSU conversion at $0.00 reflects vesting/settlement of restricted units rather than payment to exercise options.
• No indication from this filing of a 10% owner transaction or a 10b5-1 plan.